The Defense Health Agency awarded a $215,429 project grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis (MTB). This two-year project, running from July 2024 to July 2026, is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military personnel and the broader public. TB Alliance is a non-profit organization dedicated to accelerating the development of new tuberculosis (TB) drugs and treatment regimens. Through this grant, the organization will engage in cutting-edge research to develop innovative TB treatments, focusing on improving efficacy, reducing treatment duration, and addressing drug resistance. The project aligns with the program's objectives of advancing medical solutions for the battlefield and transforming health care through impactful research.
Generated 2/25/25, 4:38 AM